

Richard L Wasserman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4046317/publications.pdf>

Version: 2024-02-01

91
papers

2,359
citations

236925

25
h-index

214800

47
g-index

99
all docs

99
docs citations

99
times ranked

2429
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoglobulin replacement therapy stewardship in modern times. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 546-547.	1.0	3
2	Validation of inducible basophil biomarkers: Time, temperature and transportation. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 632-644.	1.5	7
3	An Approach to the Office-Based Practice of Food Oral Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1826-1838.e8.	3.8	44
4	Oral Immunotherapyâ€™s Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4087-4094.e3.	3.8	10
5	Exploiting nut cross-reactivity to facilitate real-world treatment of tree nut allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 149-151.	1.0	7
6	Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. <i>Frontiers in Immunology</i> , 2021, 12, 707463.	4.8	3
7	Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. <i>Immunotherapy</i> , 2021, , .	2.0	0
8	Common variable immunodeficiency and respiratory complications: take-home messages for the clinician. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 414-415.	1.0	0
9	Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8267.	4.1	13
10	Immunoglobulin replacement. , 2020, , 1143-1156.		0
11	Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 418-426.e4.	3.8	103
12	The real world is not standardized. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2098-2099.	3.8	3
13	Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAMÂ®and ASCENIVÂ®,ç. <i>Immunotherapy</i> , 2019, 11, 1423-1433.	2.0	7
14	Captaining the PIDD ship. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 419.	1.0	0
15	Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB117.	2.9	0
16	Reaching for best practices in food oral immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 129-130.e3.	1.0	14
17	Interim Safety Data in a Prospective, Open-label, Multi-center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Plasmacap Ig in Patients with Primary Immunodeficiency Diseases (Pidd). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB117.	2.9	0
18	Changing The Outcomes Of Peanut Oral Immunotherapy (POIT). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB275.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Measurement of exhaled nitric oxide in young children. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 343-345.	1.0	4
20	Personalized Therapy. <i>Immunology and Allergy Clinics of North America</i> , 2019, 39, 95-111.	1.9	28
21	Use of Genetic Testing for Primary Immunodeficiency Patients. <i>Journal of Clinical Immunology</i> , 2018, 38, 320-329.	3.8	88
22	Nut Oral Immunotherapy (NOIT) for Allergy to One Nut Desensitizes to the Cross Reactive Nut. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB241.	2.9	0
23	Balancing the risks and burdens of food allergen avoidance. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 229-230.	1.0	3
24	Nut Oral Immunotherapy (NOIT) Using Two or More Nuts Successfully Desensitizes Most Patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB258.	2.9	0
25	Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS). <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB258.	2.9	3
26	Long-Term Efficacy and Safety of Hizentra [®] in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. <i>Journal of Clinical Immunology</i> , 2018, 38, 864-875.	3.8	22
27	Oral immunotherapy for food allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 272-275.	1.0	30
28	Fractional Exhaled Nitric Oxide (FeNO) Measurements with the NIOX VERO [®] in Children 4 to 6 Years Old using the 6 and 10 Second Exhalation Modes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB104.	2.9	0
29	Identification and Characterization of Ana ^o 3 Modifications on Arginine-111 Residue in Heated Cashew Nuts. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 411-420.	5.2	13
30	Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB18.	2.9	0
31	Sustained Unresponsiveness Following Food Oral Immunotherapy (FOIT). <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB132.	2.9	0
32	Food Oral Immunotherapy (FOIT) Failures: Who and Why. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB134.	2.9	4
33	Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS). <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB134.	2.9	3
34	Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex [®] 10% Versus Gammaplex [®] 5% in Subjects with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2017, 37, 301-310.	3.8	10
35	Gammaplex [®] 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. <i>Immunotherapy</i> , 2017, 9, 1071-1088.	2.0	5
36	RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1107-1119.	3.0	18

#	ARTICLE	IF	CITATIONS
37	Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. <i>Immunotherapy</i> , 2017, 9, 1035-1050.	2.0	44
38	Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials. <i>Journal of Clinical Immunology</i> , 2017, 37, 517-518.	3.8	6
39	Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy. <i>Journal of Clinical Immunology</i> , 2017, 37, 180-186.	3.8	5
40	Case Studies. <i>Journal of Clinical Immunology</i> , 2017, 37, 188-189.	3.8	0
41	Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. <i>Journal of Clinical Immunology</i> , 2017, 37, 190-196.	3.8	20
42	Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 571-582.	3.8	37
43	Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB219.	2.9	0
44	20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 93-94.	1.0	3
45	Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB220.	2.9	1
46	Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. <i>Immunotherapy</i> , 2016, 8, 1175-1186.	2.0	30
47	The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1076-1081.e3.	3.8	10
48	Efficacy, Safety, and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease. <i>Journal of Clinical Immunology</i> , 2016, 36, 590-599.	3.8	22
49	Heat-induced alterations in cashew allergen solubility and IgE binding. <i>Toxicology Reports</i> , 2016, 3, 244-251.	3.3	32
50	Pharmacokinetics of RI-002, an Investigational Igiv Preparation. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB89.	2.9	1
51	Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB96.	2.9	2
52	Tolerance to Allergenic Foods Following Food Oral Immunotherapy (FOIT). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB28.	2.9	0
53	Single Practice Six-Year Experience Treating Food Allergy with Oral Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB27.	2.9	0
54	Treatment with oleic acid reduces IgE binding to peanut and cashew allergens. <i>Food Chemistry</i> , 2015, 180, 295-300.	8.2	20

#	ARTICLE	IF	CITATIONS
55	Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency. <i>LymphoSign Journal</i> , 2015, 2, 21-29.	0.2	3
56	Hizentra for the treatment of primary immunodeficiency. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1293-1307.	3.0	12
57	Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. <i>Immunotherapy</i> , 2014, 6, 553-567.	2.0	56
58	A new intravenous immunoglobulin (BIVIGAM [®]) for primary humoral immunodeficiency. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 325-337.	3.0	8
59	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 729.	7.4	586
60	Single Practice Five Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Effect On Antigen Specific IgE (asIgE). <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB105.	2.9	0
61	Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 91-96.e2.	3.8	91
62	In vitro digestion of soluble cashew proteins and characterization of surviving <sc>l</sc>g<sc>E</sc>-reactive peptides. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 884-893.	3.3	37
63	Decreased Immunoglobulin E (IgE) Binding to Cashew Allergens following Sodium Sulfite Treatment and Heating. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 6746-6755.	5.2	28
64	Long-term efficacy, safety, and tolerability of Hizentra [®] for treatment of primary immunodeficiency disease. <i>Clinical Immunology</i> , 2014, 150, 161-169.	3.2	29
65	Characterizing The Effect Of Sodium Sulfite On Cashew Allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB115.	2.9	0
66	Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs). <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB180.	2.9	2
67	Effect Of Oleic Acid On The Allergenic Properties Of Peanut and Cashew Allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB111.	2.9	0
68	Retrospective Analysis Of The Clinical Utility Of Biweekly Dosing With High-Concentration Subcutaneous Immunoglobulin In 10 Patients With Primary Immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB184.	2.9	1
69	Single Practice, Five-Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Successes and Failures. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB105.	2.9	0
70	Single Practice Five-Year Experience Treating Food Allergy With Oral Immunotherapy: Efficacy and Epinephrine Treated Reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB104.	2.9	1
71	Characterization of the Effects of Proteolysis and Reduction On Cashew Allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB21.	2.9	0
72	Long-Term Efficacy and Tolerability of 20% Scig in the Treatment of Patients with Primary Immunodeficiency Disease. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB157.	2.9	1

#	ARTICLE	IF	CITATIONS
73	Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 354-361.	2.2	15
74	Safety of L-proline as a stabilizer for immunoglobulin products. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 169-178.	3.0	11
75	C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 427-431.	2.2	23
76	Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 951-957.e11.	2.9	113
77	Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks. <i>Advances in Therapy</i> , 2012, 29, 913-922.	2.9	31
78	Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again. <i>Journal of Clinical Immunology</i> , 2012, 32, 1153-1164.	3.8	67
79	Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIg) in Patients with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2012, 32, 663-669.	3.8	48
80	Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf of <i>Clinical Immunology</i> , 2011, 31, 323-331.	3.8	72
81	Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2010, 30, 734-745.	3.8	125
82	Safety and Efficacy of PrivigenÂ®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2009, 29, 137-144.	3.8	87
83	Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 157-163.	2.0	51
84	Chronic Sinusitis as a Manifestation of Primary Immunodeficiency in Adults. <i>American Journal of Rhinology & Allergy</i> , 1994, 8, 29-36.	2.2	11
85	Antibody deficiency. <i>Pediatric Infectious Disease Journal</i> , 1990, 9, 424-433.	2.0	15
86	Sir., <i>Aids</i> , 1990, 4, 468.	2.2	1
87	Caustic substance injuries. <i>Journal of Pediatrics</i> , 1985, 107, 169-174.	1.8	71
88	Immunology for the Practicing Physician. <i>Pediatric Infectious Disease Journal</i> , 1984, 3, 285.	2.0	0
89	Unconventional therapies for neonatal sepsis. <i>Pediatric Infectious Disease Journal</i> , 1983, 2, 421-423.	2.0	4
90	Primary structure of the variable regions of two canine immunoglobulin heavy chains. <i>Biochemistry</i> , 1977, 16, 3160-3168.	2.5	5

#	ARTICLE	IF	CITATIONS
91	PHYLOGENETICALLY ASSOCIATED RESIDUES WITHIN THE VHIII SUBGROUP OF SEVERAL MAMMALIAN SPECIES. Journal of Experimental Medicine, 1973, 138, 410-427.	8.5	73